The amino terminus of Cdk2 binds p21

Oncology Research

Volumn 8, Issue 9, 1996, Pages 343-352

  Moskowitz, Neal K ^a   Borao, Frank J ^b   Dardashti, Omid ^a   Cohen, Hillel D ^a   Germino, F Joseph ^a  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b MONMOUTH MEDICAL CENTER   (United States)

Author keywords

Cdk inhibitors; cell cycle; CIP1; cyclin; protein protein interaction

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P21;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CELL CYCLE G1 PHASE; DRUG EFFECT; ENZYME ACTIVITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION REGULATION;

EID: 0030463026     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. 1. Morgan, D. O. Principles of Cdk regulation. Nature 374:131-134; 1995.
2. 2. Jeffrey, P.; Russo, A.; Polyak, K.; Gibbs, E.; Hurwitz, J.; Massague, J.; Pavletich, N. Mechanism of CDK activation revealed by the structure of a cyclin A-CDK2 complex. Nature 376:313-320; 1995.
3. 3. De Bondt, H.; Rosenblatt, J.; Namcarik, J.; Jones, H.; Morgan, D.; Kim, S. Crystal structure of cyclin-dependent kinase 2. Nature 363:595-602; 1993.
4. 4. Fisher, R.; Morgan, D. A novel cyclin associates with MO15/CDK7 to form the CDK-activating kinase. Cell 78:713-724; 1994.
5. 15INK4B/MTS2 related Cdk6 inhibitor, correlates with wild-type pRb function. Genes Dev. 8:2939-2952; 1994.
6. INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 371:257-261; 1994.
7. 7. Serrano, M.; Hannon, G. J.; Beach, D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclinD/CDK4. Nature 366:704-707; 1993.
8. 8. Hirai, H.; Roussel, M. F.; Kato, J.-Y.; Ashmun, R. A.; Sherr, C. J. Novel INK4 proteins, p19 and p18, are specific inhibitors of cyclin D-dependent kinase Cdk4 and Cdk6. Mol. Cell. Biol. 15:2672-2681; 1995.
9. 1NK4. Mol. Cell. Biol. 15:2682-2688; 1995.
10. 10. Hall, M.; Bates, S.; Peters, G. Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins. Oncogene 11:1581-1588; 1995.
11. 11. Hirama, T.; Koeffler, H. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 86.; 841-854; 1995.
12. 12. Kamb, A. Cell-cycle regulators and cancer. Trends Genet. 11:136-140; 1995.
13. 13. Serrano, M.; Lee, H. W.; Chin, L.; Cardon-Cardo, C.; Beach, D.; DePinho, R. Role of the INK4a locus in tumor suppression and cell mortality. Cell 85:27-37; 1996.
14. 1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78:67-74; 1994.
15. Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78: 59-166; 1994.
16. KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev. 9:639-649; 1995.
17. CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev. 9:650-662; 1995.
18. 18. Harper, J. W.; Elledge, S. J.; Keyomarsi, K.; Dynlacht, B.; Tsai, L.-H.; Zhang, P.; Dobrowolski, S.; Bai, C.; Connell-Crowley, L.; Swindell, E.; Fox, M. P.; Wei, N. Inhibition of cyclin-dependent kinases by p21.Mol. Cell. Biol. 6:387-400; 1995.
19. 19. El-Deiry, W.; Tokino, T.; Velculescu, V.; Levy, D.; Parsons, R.; Trent, J. Lin, D.; Mercer, W.; Kinzler, K.; Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825; 1993.
20. 1 cyclin-dependent kinases. Cell 75: 805-816; 1993.
21. 21. Waga, S.; Hannon, G.; Beach, D.; Stillman, B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 339:574-578; 1994.
22. 22. Li, R.; Waga, S.; Hannon, G. J.; Beach, D.; Stillman, B. Differential effects by the p21 Cdk inhibitor on PCNA-dependent DNA replication and repair. Nature 371:534-537; 1994.
23. 1 checkpoint control. Cell 82:675-684; 1995.
24. 24. Aprelikova, O.; Xiong, Y.; Liu, E. T. Both p16 and p21 families of cyclin-dependent kinase (CDK) inhibitors block the phosphorylation of cyclin-dependent kinases by the CDK-activating kinase. J. Biol. Chem. 270:18195-18197; 1995.
25. 25. Elledge, S. J; Spottswood, M. R. A new human p34 protein kinase, CDK2, identified by complementation of a cdc28 mutation in Saccharomyces cerevisiae, is a homolog of Xenopus Egl. EMBO J. 10:2653-2659; 1991.
26. Sdi1/CIP1/WAF1. EMBO J. 14:555-563; 1995.
27. 27. Wang, X.; Bhargava, A.; Sarkar, R.; Germino, F. Vectors for a 'double-tagging' assay for protein-protein interactions: localization of the CDK2-binding domain of human p21. Gene 173:147-154; 1996.
28. Cip1. Nature 375:159-161; 1995.
29. 29. Chen, J.; Jackson, P. K.; Kirschner, M. W.; Dutta, A. Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature 374:386-388; 1995.
30. Cip1/WaF1 peptide domains required for cyclinD/Cdk2 and PCNA interaction. Oncogene 12:595-607; 1996.
31. Cip1 cyclin-dependent kinase inhibitor. Oncogene 10:2281-2287; 1995.
32. 32. Germino, F.; Wang, Z.; Weissman, S. Screening for in vivo protein-protein interactions. Proc. Natl. Acad. Sci. USA90:933-937; 1993.
33. 33. Wang, Z.; Germino, F. J. Mutational analysis of the conserved region 2 site of adenovirus E1a and its effect on binding to the retinoblastoma gene product: use of the "double-tagging" assay. Proc. Natl. Acad. Sci. USA92:4631-4635; 1995.
34. Kip1 cyclin-dependent-kinase inhibitor bound to the cyclinA-Cdk2 complex. Nature 382:325-331; 1996.